In contrast, Eylea and Lucentis cost ~$1,800 and $2.000, respectively. Other major competitor drugs for Eylea are Novartis’s (NVS) Visudyne and Pfizer’s (PFE) Macugen.

Regeneron Pharmaceuticals beat Wall Street estimates for second-quarter revenue and profit on Friday helped by robust demand ...

If approved, EYLEA HD would be the first and only treatment for RVO indicated for up to every 8-week dosing after an initial monthly dosing period – halving the number of injections that are ...

TARRYTOWN, N.Y., Oct. 18, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive three-year (156-week) data for EYLEA HD ® (aflibercept) Injection 8 mg ...

If approved, EYLEA HD would be the first and only treatment for RVO indicated for up to every 8-week dosing after an initial monthly dosing period – halving the number of injections that are ...